The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma

Condition	Treatment or Intervention	Phase
Melanoma	Drug: CP-675,206	Phase II

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

Histologically confirmed: Stage III (AJCC 6th edition)xxl unresectable melanoma, with measurable disease (either locally relapsed unresectable, in-transit lesions or unresectable draining nodes) or Stage IV melanoma, including:

• Metastasis to skin, subcutaneous tissues or distant lymph nodes, or
• Metastasis to lungs, or
• Metastasis to all other visceral sites with either LDH <= ULN (upper limit of normal) or a single site of metastasis

Note: Patients with melanoma of ocular origin will be considered ineligible

Documented progressive disease following adjuvant therapy, localized therapy or other therapy for metastatic disease

Measurable disease defined by at least one target lesion that can be accurately measured and whose size is at least 1.0 cm (by spiral CT) or 2.0 cm (by conventional techniques) in its longest diameter

ECOG performance status of 0 or 1 (see Appendix H)

Life expectancy of > 3 months

Either gender, aged 18 years and above

Adequate bone marrow, hepatic, and renal functions determined within 2 weeks prior to starting therapy, defined as:

• Absolute neutrophil count >= 1.5 x 10(9)cells/L
• Platelets >= 100 x 10(9)/L
• Hemoglobin >= 10 g/dL
• Aspartate and alanine aminotransferases (AST, ALT) <= 2.5 x ULN (<= 5 x ULN, if documented liver metastases are present)
• Total bilirubin <= 1.5 x ULN
• Creatinine <= 1.5 x ULN

Patients must have recovered from all prior treatment related toxicities, to baseline status, or a CTC grade of 0 or 1. Post-surgical pain shall not be considered a basis for exclusion.

Females must either be not of childbearing potential [surgically sterilized, which includes tubal ligation, or at least 2 years postmenopausal; not breastfeeding], or practicing 1 form of approved contraception for at least three months prior to entry into the study with 1 of the following methods: (a) oral contraceptives, (b) intrauterine device, (c) implanted contraceptive (such as Norplant®), (d) injected contraceptives (such as Depo-Provera®), (e) diaphragm, (f) sexual partner must use condom or be surgically sterilized, or (g) sexually inmotive. Females of childbearing potential must be instructed to avoid pregnancy during study participation. Negative serum or urine pregnancy test must be documented during screening evaluation.

Must be willing and able to provide written informed consent.

ONLY for patients enrolled in the expansion portion of the study, presence of HLA tissue subtype, A*0201 (see Section 3.2.3.3).

Exclusion Criteria:

• Received immunotherapy for cancer within one month prior to the start of screening
• Received > 2 doses of previous CP-675,206
• Patients previously treated on this protocol
• History of, or significant evidence of risk for, chronic inflammatory or autoimmune disease (e.g. Addison’s disease, asthma, celiac disease, multiple sclerosis, Graves Disease, Hashimoto’s thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, etc.)
• Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history.
• History of autoimmune colitis or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin.
• Pregnant or lactating women (see Section 3.1.1, criteria 10).
• Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
• Diagnosed or suspected brain metastases. Patients with past history of brain metastases but with no radiologic evidence within 12 weeks prior to enter into the protocol will be eligible.
• Any serious uncontrolled medical disorder or active infection, which would impair their ability to receive study treatment.
• Coexisting malignancies except for basal or squamous cell carcinoma of the skin.

Dr. Viviana A Bozon, MD      860-732--9916    Viviana.Bozon@Groton.Pfizer.com

California
      Pfizer Investigational Site, Los Angeles,  California,  90095,  United States; Recruiting
New Hampshire
      Pfizer Investigational Site, Lebanon,  New Hampshire,  03756,  United States; Not yet recruiting
Texas
      Pfizer Investigational Site, Houston,  Texas,  77030,  United States; Recruiting

Study ID Numbers:  A3671002
Record last reviewed:  November 2004
Record first received:  July 1, 2004
ClinicalTrials.gov Identifier:  NCT00086489
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-17